ECSP088971A - Ligandos 101 de los receptores nicotínicos de acetilcolina - Google Patents

Ligandos 101 de los receptores nicotínicos de acetilcolina

Info

Publication number
ECSP088971A
ECSP088971A EC2008008971A ECSP088971A ECSP088971A EC SP088971 A ECSP088971 A EC SP088971A EC 2008008971 A EC2008008971 A EC 2008008971A EC SP088971 A ECSP088971 A EC SP088971A EC SP088971 A ECSP088971 A EC SP088971A
Authority
EC
Ecuador
Prior art keywords
acetilcoline
ligandos
nicotinic receptors
methods
diastomers
Prior art date
Application number
EC2008008971A
Other languages
English (en)
Inventor
Thomas R Simpson
James Woods
Hui-Fang Chang
Christopher Holmquist
Eifion Phillips
Timothy PISER
Rebecca Urbanek
Hui Xiong
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088971A publication Critical patent/ECSP088971A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ligandos de los receptores nicotínicos de acetilcolina de Fórmula I, donde X, n R1 y R2 son descritos en la descripción, diastómeros, enantiómeros, sales farmacéuticamente aceptables, métodos de producción, composiciones farmacéuticas que los contienen y métodos de uso de los mismos.
EC2008008971A 2006-05-17 2008-12-12 Ligandos 101 de los receptores nicotínicos de acetilcolina ECSP088971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74747606P 2006-05-17 2006-05-17
US82497506P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
ECSP088971A true ECSP088971A (es) 2009-01-30

Family

ID=38694158

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008971A ECSP088971A (es) 2006-05-17 2008-12-12 Ligandos 101 de los receptores nicotínicos de acetilcolina

Country Status (19)

Country Link
US (2) US7842803B2 (es)
EP (1) EP2019831B1 (es)
JP (1) JP2009537517A (es)
KR (1) KR20090007753A (es)
AR (1) AR060914A1 (es)
AU (1) AU2007250560B2 (es)
BR (1) BRPI0711941A2 (es)
CA (1) CA2652610A1 (es)
CL (1) CL2007001405A1 (es)
EC (1) ECSP088971A (es)
ES (1) ES2392997T3 (es)
IL (1) IL195019A0 (es)
MX (1) MX2008014436A (es)
NO (1) NO20084915L (es)
RU (1) RU2441007C2 (es)
SA (1) SA07280244B1 (es)
TW (1) TW200813067A (es)
UY (1) UY30349A1 (es)
WO (1) WO2007133155A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2009066107A1 (en) * 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α7活化劑之用途
CN103442701A (zh) 2011-01-27 2013-12-11 诺瓦提斯公司 烟碱乙酰胆碱受体α7激活剂的用途
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
EP2768507B1 (en) 2011-10-20 2019-12-11 Novartis AG Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
ES2661050T3 (es) 2012-12-11 2018-03-27 Novartis Ag Biomarcador predictivo de la capacidad de respuesta a tratamiento con activador del receptor nicotínico de acetilcolina alfa-7
BR112015016994A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
CN105246485B (zh) 2013-01-15 2019-03-15 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂的应用
BR112015016995B8 (pt) 2013-01-15 2022-07-26 Novartis Ag Uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
WO2017156309A1 (en) * 2016-03-09 2017-09-14 Msato, Llc Pellet shaped marking round for air rifles and pistols
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DE60218032T2 (de) * 2001-06-01 2007-08-16 Astrazeneca Ab Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren
KR20040099447A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 푸릴 화합물
NZ535978A (en) * 2002-04-18 2007-10-26 Astrazeneca Ab Novel spiroazabicyclic heterocyclic amines useful as nicotinic acetylcholine receptor agonists
KR20040099446A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 헤테로시클릭 화합물
BRPI0414633A (pt) * 2003-09-25 2006-11-07 Astrazeneca Ab composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit

Also Published As

Publication number Publication date
US7842803B2 (en) 2010-11-30
BRPI0711941A2 (pt) 2011-12-13
EP2019831A1 (en) 2009-02-04
UY30349A1 (es) 2008-01-02
CL2007001405A1 (es) 2008-01-25
US20110136804A1 (en) 2011-06-09
EP2019831B1 (en) 2012-09-12
US20080139600A1 (en) 2008-06-12
AU2007250560A1 (en) 2007-11-22
RU2008143450A (ru) 2010-06-27
KR20090007753A (ko) 2009-01-20
JP2009537517A (ja) 2009-10-29
SA07280244B1 (ar) 2011-06-22
TW200813067A (en) 2008-03-16
ES2392997T3 (es) 2012-12-17
RU2441007C2 (ru) 2012-01-27
AR060914A1 (es) 2008-07-23
AU2007250560B2 (en) 2011-06-23
EP2019831A4 (en) 2010-06-09
MX2008014436A (es) 2008-11-27
NO20084915L (no) 2009-02-13
WO2007133155A1 (en) 2007-11-22
IL195019A0 (en) 2009-08-03
CA2652610A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
ATE483707T1 (de) 2-cyclopropylthiazolderivate
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP067077A (es) Derivados de pirrolopiridina y su uso como antagonistas de crth2
NO20083630L (no) Nye pyridinderivater
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
NO20073551L (no) Nikotinacetylkolinreseptorligander
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
MX2010001574A (es) Ligandos del receptor cannabinoide.
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
NZ552137A (en) New 4-benzylidene-piperidin derivatives
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
UY30121A1 (es) Nuevos compuestos
HRP20080174A2 (hr) Derivati benzotiazol ciklobutil amina i njihova uporaba kao liganda histamin-3-receptora
UY28687A1 (es) Ligandos del receptor de acetilcolina nicotinica